The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Engineered Antibodies with Increased Activity to Recruit Complement
Open accessAbstract
This manuscript describes two sites in a human IgG1 that, when mutated individually or in combination, result in a dramatic increase in C1q binding and complement-dependent cytotoxicity activity. These two residues, K326 and E333, are located at the extreme ends of the C1q binding epicenter in the CH2 domain of a human IgG. A mutation to tryptophan at K326 debilitates Ab-dependent cell-mediated cytotoxicity activity. In addition, substitutions of the residues E333 with serine and of K326 with tryptophan in a human IgG2 confer biological activity in the complement-dependent cytotoxicity assay in which the wild-type IgG2 is inactive. This study reveals that the residues K326 and E333 play a significant role in the control of the biological activity of an IgG molecule and can rescue the activity of an inactive IgG isotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid and efficient site-specific mutagenesis without phenotypic selection.
Kunkel, T. A. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.2.488 · Cited by 7,206
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Principles of protein structure
(1980) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(80)90019-9 · Cited by 1,058
Additivity of mutational effects in proteins
Wells, J. A. (1990) · Biochemistry · doi:10.1021/bi00489a001 · Cited by 646
The binding site for C1q on IgG
Duncan, A. R., & Winter, G. (1988) · Nature · doi:10.1038/332738a0 · Cited by 569
Immunoglobulin G: Functional sites
Burton, D. R. (1985) · Molecular Immunology · doi:10.1016/0161-5890(85)90151-8 · Cited by 433
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Self-citationBiology of Human Immunoglobulin G Fc Receptors
van de Winkel, J. G. J., & Anderson, C. L. (1991) · Journal of Leukocyte Biology · doi:10.1002/jlb.49.5.511 · Cited by 392
Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90521-5 · Cited by 350
Jefferis, R., Lund, J., & Pound, J. D. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01188.x · Cited by 329
Eaton, D. L., Wood, W. I., Eaton, D., Hass, P. E., Hollingshead, P., Wion, K., Mather, J., Lawn, R. M., Vehar, G. A., & Gorman, C. (1986) · Biochemistry · doi:10.1021/bi00374a001 · Cited by 267
Human Antibody Effector Function
Burton, D. R., & Woof, J. M. (1992) · Advances in Immunology · doi:10.1016/s0065-2776(08)60486-1 · Cited by 265
Anderson, D. R., Grillo-López, A., Varns, C., Chambers, K. S., & Hanna, N. (1997) · Biochemical Society Transactions · doi:10.1042/bst0250705 · Cited by 248
Wormald, M. R., Rudd, P. M., Harvey, D. J., Chang, S.-C., Scragg, I. G., & Dwek, R. A. (1997) · Biochemistry · doi:10.1021/bi9621472 · Cited by 191
Magee, J. C., Collins, B. H., Harland, R. C., Lindman, B. J., Bollinger, R. R., Frank, M. M., & Platt, J. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118297 · Cited by 188
Papac, D. I. (1998) · Glycobiology · doi:10.1093/glycob/8.5.445 · Cited by 151
Reaction between the isolated globular sub-units of the complement component Clq and IgG-complexes
Hughes-Jones, N. C., & Gardner, B. (1979) · Molecular Immunology · doi:10.1016/0161-5890(79)90010-5 · Cited by 135
Transient production of proteins using an adenovirus transformed cell line
Gorman, C., Gies, D. R., & McCray, G. (1990) · Cited by 122
A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody
Gazzano, H., Ralph, P., Ryskamp, T., Chen, A. B., & Mukku, V. R. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00002-1 · Cited by 55
Sensel, M. G., Kane, L. M., & Morrison, S. L. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00112-0 · Cited by 34
ROLE OF Fc FRAGMENTS IN INHIBITION OF XENOGENIC HYPERACUTE REJECTION BY INTRAVENOUS IMMUNOGLOBULIN
Kojima, T., Hayashi, S., Yokoyama, I., & Takagi, H. (1996) · Transplantation · doi:10.1097/00007890-199609150-00003 · Cited by 11
Cited by
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Metadata
- Authors
- Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-02
- Volume
- 166
- Issue
- 4
- Pages
- 2571-2575
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1589026573
- Cited by
- 291
- References
- 24
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.